Atherosclerosis Drugs Market Size, Share, Opportunities, And Trends By Drug Class (Anti-platelet Medications, Cholesterol Lowering Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Beta Blockers, Others), By Route Of Administration (Injectable, Oral), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), And By Geography - Forecasts From 2024 To 2029

The atherosclerosis drugs market is anticipated to expand at a high CAGR over the forecast period.

The market for atherosclerosis includes a variety of medications, equipment, and therapies used to prevent and treat the disorder that is typified by the accumulation of plaque in artery walls. There are numerous opportunities and problems in this sector. Although dietary and activity modifications are still the cornerstones of controlling atherosclerosis, prescription medications like statins, antiplatelet medicines, and antihypertensive meds are also frequently administered. Patients with atherosclerosis may benefit from novel treatments that target inflammation, such as PCSK9 inhibitors and monoclonal antibodies. These treatments have the potential to lower cardiovascular risk.

Furthermore, severe disease states are addressed by interventional procedures like stent implantation and angioplasty. Problems include the increasing global prevalence of atherosclerosis, especially in elderly populations, and the rising rates of diabetes and obesity. Healthcare organizations frequently struggle with the financial strain of treating issues linked to atherosclerosis, like heart attacks and strokes.

Market Drivers:

• Growing prevalence is anticipated to boost the atherosclerosis drugs market growth.

The escalating prevalence of atherosclerosis, influenced by factors such as aging populations, sedentary lifestyles, poor dietary habits, and increasing obesity rates, is a primary driver of the atherosclerosis drugs market. This heightened disease burden fuels the demand for effective treatments and preventive measures. Healthcare systems prioritize diagnosis and management, leading to increased investment in research, development, and innovation. Moreover, rising awareness about atherosclerosis risk factors and symptoms encourages early intervention and treatment-seeking behavior among affected individuals. As the prevalence continues to grow globally, the market for atherosclerosis treatments expands to meet the evolving healthcare needs of patients.

According to the CDC, as listed by ethnicity, race, and sex, 22.6% of deaths of the Black (non-Hispanic) population and 15.5 deaths of American Indians are caused by Heart Attacks.

• Technological advancements are expected to boost the Atherosclerosis drugs market.

Technological developments are improving patient outcomes, diagnosis, and treatment of atherosclerosis, which is transforming the market. The ability to precisely visualize arterial plaques is made possible by innovations like sophisticated imaging modalities like intravascular ultrasound (IVUS) and optical coherence tomography (OCT), which help with diagnosis and therapy planning. Furthermore, safer and more effective therapies are made possible by the advancement of minimally invasive techniques such as drug-eluting stents and atherectomy devices.

Additionally, new technologies like wearables and artificial intelligence (AI) present chances for remote monitoring and customized risk assessment, which can improve illness management tactics. These innovations in technology propel advancement, enhance patient care, and support the market expansion for atherosclerosis.

In March 2023, Results from the Phase 2b clinical trial assessing MK-0616, an experimental once-daily oral proprotein convertase subtilisin/kexin type 9 inhibitor, in adults with hypercholesterolemia, were released by Merck, also known as MSD. The study's main goal was to compare the four dosages of MK-0616 vs placebo in terms of the percentage change in low-density lipoprotein cholesterol from baseline to week eight. By week eight, LDL-C was much lower in all MK-0616 doses when compared to placebo; the placebo-adjusted reduction from baseline was between 41.2% and 60.9%. These data were concurrently published in the Journal of The American College of Cardiology and presented at the 72nd Annual Scientific Session of the American College of Cardiology in conjunction with the World Congress of Cardiology (ACC.23/WCC).

• Drug innovations are anticipated to propel the atherosclerosis drug market.

The market for atherosclerosis is mostly driven by drug breakthroughs, with continuing research concentrating on cutting-edge treatments that address different facets of the condition. The creation of next-generation statins with enhanced safety and efficacy profiles and novel treatments aimed at lipid metabolism, inflammation, and plaque stabilization are examples of advancements. Potential advantages of these novel medications include fewer cardiovascular events, better patient outcomes, and increased treatment compliance.

Additionally, the development of gene therapies, biologic medicines, and RNA-based treatments promises to address unmet medical requirements in the effective management of atherosclerosis and propel market expansion through individualized treatment approaches.

Asia Pacific region is expected to grow significantly.

The market for atherosclerosis is expanding significantly in the Asia-Pacific area for several reasons. The increasing incidence of cardiovascular disorders, such as atherosclerosis, can be attributed to factors such as aging populations, fast urbanization, and the adoption of Western lifestyles. Market growth is also fueled by rising healthcare costs, more availability of cutting-edge therapies and diagnostics, and government programs that promote cardiovascular health.

The Asia-Pacific atherosclerosis market is also expanding as a result of the increased emphasis on preventive healthcare and a growing understanding of the value of early intervention in cardiovascular diseases. Furthermore, new treatments specifically designed to meet the specific requirements of patients in the Asia-Pacific area are being introduced as a result of research and development breakthroughs. As a result, the regional market for atherosclerosis drugs is expected to continue expanding.

 Market Restraints:

• Complexity of atherosclerosis can constrain the market for atherosclerosis drugs.

The complexity of atherosclerosis necessitates a multimodal approach to treatment, which is one of the main obstacles facing the industry. It is still difficult to develop treatments that successfully address many facets of atherosclerosis, such as lipid buildup, inflammation, and plaque stability. It can also be challenging to guarantee that patients follow their treatment plans, especially when it comes to long-term pharmaceutical use and lifestyle changes. To overcome these obstacles, ongoing research and innovation are needed to provide more individualized, patient-centered treatment plans that successfully manage atherosclerosis and lower related cardiovascular risks.

Market Development:

• January 2024 - A clinical-stage biopharmaceutical business called TransThera, which is committed to developing unique medications worldwide, has announced that IND-enabling trials for TT-02332, a strong, specific, and extremely CNS-permeating NLRP3 inflammasome inhibitor, have begun. The NLRP3 inflammasome is an essential element of the human innate immune system. Several inflammatory conditions, such as obesity, neurodegenerative illnesses, NASH, inflammatory bowel disease (IBD), dermatitis, and atherosclerosis, are closely associated with aberrant activation of NLRP3.
• July 2023 - Leqvio has a label update that the US Food and Drug Administration (FDA) has authorized, allowing for earlier use as an adjuvant to diet and statin therapy in patients with elevated LDL-C who have an increased risk of heart disease, according to Novartis. For individuals who have not experienced a coronary event but are at an elevated risk of heart disease, Leqvio can now be taken early in the course of LDL-C treatment as an addition to diet and statin therapy. The updated label supports strong safety and efficacy information for Leqvio.

Market Segmentation:

• By Drug Class
  • Anti-platelet Medications
  • Cholesterol Lowering Medications
  • Fibric Acid and Omega-3 Fatty Acid Derivatives
  • Beta Blockers
  • Others
• By Route of Administration
  • Injectable
  • Oral
• By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
• By Geography
  • • North America
    • United States
    • Canada
    • Mexico
    • South America
    • Brazil
    • Argentina
    • Others
    • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Others
    • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
    • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others